Assessing the incidence of papillomavirus infections in France;Estimation de l'incidence des infections à papillomavirus en France

Gynecologie Obstetrique et Fertilite

Volumn 37, Issue 2, 2009, Pages 125-130

  Detournay, B ^a   Granados Canal, D ^b   El Hasnaouil, A ^b  

^a CEMKA EVAL   (France)

^b GLAXOSMITHKLINE   (France)

Author keywords

Epidemiology; Incidence; Papillomavirus

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CYTODIAGNOSIS; FEMALE; FRANCE; HIGH RISK ONCOGENIC HUMAN PAPILLOMAVIRUS; HIGH RISK POPULATION; HUMAN; INCIDENCE; PREVALENCE; SCHOOL CHILD; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; VIRUS REACTIVATION; WART VIRUS;

EID: 61349098761     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2008.11.012     Document Type: Article

References (27)

1. Étude collaborative FRANCIM, hospices civils de Lyon, InVS, CepiDC. Évolution de l'incidence et de la mortalité par cancer en France de 1980 à 2005. 30 janvier 2008. http://www.invs.sante.fr/surveillance/cancers.
2. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J.F., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
3. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
4. Richardson H., Kelsall G., Tellier P.P., Abrahamowicz M., Coutlée F., and Franco E.L. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol Biomarkers Prev 12 (2003) 485-490
5. Sellors J.W., Karwalajtys T.L., Kaczorowski J., Mahony J.B., Lytwyn A., Chong S., et al. Survey of HPV in Ontario Women Group. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168 (2003) 421-425
6. Riethmuller D., Gay C., Bertrand X., Bettinger D., Schall J.P., and Carbillet J.P. Genital human papillomavirus infection among women recruted for the routine cervical cancer screening or for colposcopy by HC2 and PCR. Diagn Mol Pathol 8 (1999) 157-164
7. Clavel C., Masure M., Bory J.P., Putaud I., Mangeonjean C., Lorenzato M., et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 89 (2001) 1616-1623
8. Beby-Defaux A., Bourgoin A., Ragot S., Battandier D., Lemasson J.M., Renaud O., et al. The practitioners of the centre d'examens de santé de la caisse primaire d'Assurance maladie de la Vienne et Agius G. Human papillomavirus infection of the cervix uteri in women attending a health examination center of the French social security. J Med Virol 73 (2004) 262-268
9. Dalstein V., Riethmuller D., Pretet J.L., Le Bail Carval K., Sautiere J.L., Carbillet J.P., et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 106 (2003) 396-403
10. Boulanger J.C., Sevestre H., Bauville E., Ghighi C., Harlicot J.P., and Gondry J. Épidémiologie de l'infection à HPV. Gynecol Obstet Fertil 32 (2004) 218-223
11. Cuzick J., Clavel C., Petry K.-U., Meijer C.J.L.M., Hoyer H., Ratman S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J cancer 119 (2006) 1095-1101
12. Schiffman M., and Krüger Kjaer S. Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr 31 (2003) 14-19
13. Plummer M., Schiffman M., Castle P.E., Maucourt-Blouch D., Wheeler C.M., and for the ALTS Group. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of underterminated significance or low-grade squamous intraepithelial lesion. JID 195 (2007) 1582-1589
14. Bory J.P., Cucherousset J., Lorenzato M., Gabriel R., Quereux C., Birembaut P., et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3091 women. Int J Cancer 102 (2002) 519-525
15. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362 (2003) 1871-1876
16. Kibur M., Af Geijerstamm V., Pukkala E., Koskela P., Luostarinen T., Paavonen J., et al. Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV 16 vaccination. Sex Transm Infect 76 (2000) 13-17
17. ANRS, Inserm, Ined. Enquête CSF « Contexte de la sexualité en France ». Premiers résultats. Dossier de presse 2007.
18. Global sex survey http://www.durex.com/fr/gss2005results.asp.
19. Lydié N., and Léon C. Sexualité, IST et dépistage du VIH. Barometre Sante Premiers Resultats (2005) 109-117
20. Syrjanen S., Shabalova I., Petrovichev N., Podistov J., Ivanchenko O., Zakharenko S., et al. Age-specific incidence and clearance of high-risk human papillomavirus infections in women in the former Soviet Union. Int J STD AIDS 16 (2005) 217-223
21. Enquête OMS sur la santé des jeunes, 2000, http://www.euro.who.int.
22. Anhang R., Goodman A., and Goldie S.J. HPV communication: review of existing research and recommandations for patient education. CA Cancer J Clin 54 (2004) 248-259
23. CDC. Tracking the hidden epidemics 2000. Trends by disease. Human Papillomavirus (HPV), 2005. http://www.cdc.gov/nchstp/od/news/RevBrochure1pdfhpv.htm.
24. Dalstein V., Prétet J.L., and Mougin C. Histoire naturelle de l'infection cervicale à HPV muqueux. In: Aubin F., Prétet J.L., and Mougin C. (Eds). Papillomavirus humains. Biologie et pathologie tumorale (2003), Éditions TEC & TOC et Éditions Médicales Internationales, France p. 759
25. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., Manos M.M., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 (2001) 8-15
26. Ho G.Y., Studentsov Y., Hall C.B., Bierman R., Beardsley L., Lempa M., et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186 (2002) 737-742
27. Viscidi R.P., Schiffman M., Hildesheim A., Herrero R., Castle P.E., Bratti M.C., et al. Seroreactivity to human papillomavirus (HPV) types 16, 18 or 31 and risk of subsequent HPV infection: results from a populationbased study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13 (2004) 324-327